Navigation Links
New test discovered to better predict breast cancer outcomes
Date:1/27/2011

Researchers from McGill University's Rosalind and Morris Goodman Cancer Research Centre (GCRC), the Research Institute of the McGill University Health Centre (RI MUHC), the DanaFarber Cancer Institute and Harvard Medical School have discovered a gene signature that can accurately predict which breast cancer patients are at risk of relapse, thereby sparing those who are not from the burdens associated with unnecessary treatment.

For years, clinicians have been faced with the problem that breast cancer cannot be treated with a one-size-fits-all approach. Some cancers respond to specific treatments while others do not. Close to 50 per cent of breast cancer patients belong to a group defined as "estrogen receptor positive/lymph node negative (ER+/LR-)" that is at low risk of relapse. The majority of patients in this group may not require any treatment beyond the surgical removal of their tumour, while a small minority should receive additional treatment.

"The added information provided by our test would enable oncologists to identify those at very low risk of relapse, for whom the risk-benefit ratio might be in favour of withholding chemotherapy, and to identify patients in this low-risk group who would benefit from more aggressive treatments," explains Dr. Alain Nepveu, GCRC and RI MUHC researcher and co-author of the study. "Since many treatments are associated with short- and long-term complications including premature menopause, cardiotoxicity and the development of secondary cancers, risks must be balanced against the potential benefit for each patient to avoid unnecessary suffering, needless expense and added burdens on the health-care system."

While more research is required before the test would be ready for market and incorporated into existing diagnostic procedures, Nepveu suggests it has the potential to be commercialized within five years.


'/>"/>

Contact: Allison Flynn
allison.j.flynn@mcgill.ca
514-972-3934
McGill University
Source:Eurekalert

Page: 1

Related medicine news :

1. First Gene Variants Linked to Stuttering Discovered
2. Researchers Who Discovered First Genes for Stuttering will Present Findings to the National Stuttering Association
3. Genes Behind Tooth Development Discovered
4. Genetic cause discovered for rare bleeding disorder
5. Gene discovered for newly recognized disease in Amish children
6. Clinical benefit of multiple sclerosis drug discovered at Rush University Medical Center
7. Genetic pattern that predicts leukemia relapse discovered
8. Researchers report new autism genes discovered
9. New function discovered in cancer-prevention protein
10. New strain of bacteria discovered that could aid in oil spill, other environmental cleanup
11. Early detection of cancer: The FDA approves procedure discovered by EPFL researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... , ... MelaKids, a Laredo-based company, has introduced a new concept for children’s ... gives us a full supply of melanin – in the back of the eye ... pigment; however, around the age of thirty, we develop a yellow-brown pigment in the ...
(Date:9/19/2017)... , ... September 19, 2017 , ... The Workgroup ... of health IT to create efficiencies in healthcare information exchange and a trusted advisor ... of their latest industry white paper, entitled Barriers to Adoption of the ERA ...
(Date:9/19/2017)... ... ... Public outrage over the toxins that exist in tap water and the lack ... itself to research, develop and ultimately supply consumers with healthy drinking water alternatives. Vitev ... alkaline water technologies, water filtration systems, and consumer education. , ...
(Date:9/19/2017)... ... September 19, 2017 , ... Bone Solutions Inc. (BSI), an ... orthopedic medical device, OsteoCrete®. OsteoCrete® bone void filler is designed to assist with ... magnesium, a critical property for bone health and development. , “We’re excited to ...
(Date:9/19/2017)... ... September 19, 2017 , ... Ron Norman, CEO of Team Decades, ... of making a distinct rather than generic impression in the job market if one ... a stack of resumes knows that the first impression they give off is not ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... Sept. 6, 2017   PDI , a leader in ... host an educational session focused on the role of ... prevention at the 2017 Annual Scientific Meeting of the ... place at the Phoenix Convention ... Sept. 16-19, will also feature PDI,s Prevantics® Device ...
(Date:9/6/2017)... 2017 Eli Lilly and Company (NYSE: ... data for galcanezumab and lasmiditan, two investigational treatments for ... Society (IHC) taking place Sept. 7-10 in ... new, long-term data from an open-label study evaluating the ... mg and 240 mg) for the prevention of migraine. ...
(Date:9/5/2017)... NEWTOWN, Pa. , Sept. 5, 2017  Xyntek Inc. has announced another ... opened a new Midwest office to meet the growing demands of customer engagements ... Xyntek's new Midwest office is located at ... ... demands of customer engagements regionally. ...
Breaking Medicine Technology: